Abstract 1646P
Background
Approximately 90% of pancreatic cancer patients carry KRAS mutations, and about 80% of pancreatic cancer patients are diagnosed at advanced stage with poor efficacy of first-line treatment. Currently, several anti-tumor small molecule drugs targeting KRAS are under clinical investigation. Exploring the genomic and prognostic information of KRAS-mutated patients can help identify suitable pancreatic cancer patients for targeted therapy.
Methods
From 2017 to 2020, a total of 487 tumor samples were collected from pancreatic cancer patients across China. The laboratory Origimed, certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), conducted next-generation sequencing (NGS) of 450 cancer-related genes (YUANSUTM) in Shanghai, China.
Results
In this study, we found that among 487 patients with pancreatic cancer, the percentages of KRAS G12, non-G12 KRAS mutations, and KRAS wild-type were 79.9%, 7.8%, and 12.3%, respectively. Furthermore, we found that pancreatic cancer patients with KRAS mutations were more likely to have TP53 mutations (82.2% vs 78.4% vs 48.3%, p=9.7x10-8), while BRAF (23.3% vs 2.6% vs 0.5%, p=3.0x10-11) and CTNNB1 (21.7% vs 5.3% vs 1.3%, p=1.2x10-8) were more common mutated genes in KRAS wild-type patients. We found that patients with non-G12 mutations had significantly higher TMB than those with G12 mutations and KRAS wild-type (4.1 vs 2.3, p=0.0008), and this group of patients had significantly lower OS after receiving first-line chemotherapy in our cohort (249 days VS 352 days VS NA, p=0.013), but no difference was observed in PFS.
Conclusions
In this study, we elucidated the genomic differences among pancreatic cancer patients with KRAS G12, non-G12, and KRAS wild-type mutations. Furthermore, we found that patients with non-G12 KRAS mutations had lower OS after receiving first-line chemotherapy compared to other patients, and these patients had higher TMB levels.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22